Advancing Inflammatory Disease Treatment: Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Jason Kolbert, Managing Director of Healthcare Research at D. Boral Capital and Dr. Roger Pomerantz, M.D. & Vice Chairman of Enlivex Therapeutics moderate an exclusive virtual panel discussion featuring Professor Philip Conaghan MBBS, PhD, FRACP, FRCP, a leading clinician scientist working in the field of musculoskeletal medicine and Professor Ali Mobasheri BSc, ARCS, MSc, DPhil (Oxon), a leading scientist working in the area of musculoskeletal biology.
This webinar explores recent breakthroughs in treatment approaches, with a focus on new clinical insights from Enlivex’s knee osteoarthritis program.
This expert panel provides key perspectives on the evolving therapeutic landscape for musculoskeletal conditions, discusses the role of Allocetra in treating knee pain, and dives into the significance of the latest data.
Disclaimers:
Enlivex Therapeutics Ltd. (ENLV) is currently or has been considered to be a client of D. Boral Capital, or one of its affiliates, within the past 12 months.
D. Boral Capital or its affiliates provide Investment Banking Services to Enlivex Therapeutics Ltd. (ENLV).
D. Boral Capital, or its affiliates, have received compensation from Enlivex Therapeutics Ltd. (ENLV) for investment banking services within the past 12 months.